参考文献: [1]Janjigian Y Y, Shitara K, Moehler M, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomi...
[4] Goldstraw P, Chansky K, Crowley J, et al. The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer. J Thorac Oncol 2016;11:39-51. [5] Pignon JP, TribodetH, Scagliotti G...
CheckMate -9ER is an open-label, randomized, multi-national Phase 3 trial evaluating patients with previously untreated advanced or metastatic renal cell carcinoma (RCC). A total of 651 patients (23% favorable risk, 58% intermediate risk, 20% poor risk; 25% PD-L1≥1%) were ...
while WBRT is reserved for those with high tumor burden [75]. The median OS of NSCLC patients receiving traditional therapies is between 7 and 9 months [76]. Thus, it is imperative to explore new therapies that can improve the low OS. ...
Background Previously, findings from CheckMate 238, a double-blind, phase 3 adjuvant trial in patients with resected stage IIIB–C or stage IV melanoma, showed significant improvements in recurrence-free survival and distant metastasis-free survival with nivolumab versus ipilimumab. This report provides...
PFS: The combination doubled median PFS (17.0 months vs. 8.3 months, respectively; HR 0.52; 95% CI: 0.43 to 0.64), the trial’s primary endpoint, compared to sunitinib. ORR: Nearly twice as many patients responded toOPDIVOin combination withCABOMETYXvs. sunitinib (54.8% ...
非小细胞肺癌(NSCLC)病例占所有已诊出肺癌病例的85%,并且是全球肺癌发病率和死亡率的首要原因之一[1]。大多数病例在晚期被诊断出来,但有高达25%的病例表现为可切除 ,这具有潜在的治愈可能[2]。在接下来的几年中,由于筛查计划的推行,这一比例可能会增加[3]。但令人遗憾的是,单纯手术后的预后并不乐观,Ⅲ期疾病...